| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue, net | 8,756 | 9,232 | 11,515 | 12,295 |
| Cost of revenue | 3,317 | 3,956 | 4,145 | 4,789 |
| Gross profit | 5,439 | 5,276 | 7,370 | 7,506 |
| Sales and marketing | 2,087 | 2,910 | 2,814 | 2,864 |
| Research and development | 150 | 173 | 177 | 199 |
| General and administrative | 2,057 | 2,661 | 2,550 | 2,538 |
| Total operating expenses | 4,294 | 5,744 | 5,541 | 5,601 |
| Operating income from continuing operations | 1,145 | -468 | 1,829 | 1,905 |
| Other nonoperating expense | - | - | - | 394 |
| Note payable interest | 30 | 49 | 78 | 141 |
| Interest accretion expense | - | 0 | - | 4 |
| Other expense, net | -115 | -16 | 21 | - |
| Income from continuing operations before tax | 1,000 | -533 | 1,772 | 1,366 |
| (benefit) provision for income taxes | -11 | 0 | 18 | 4 |
| Income from continuing operations | 1,011 | -533 | 1,754 | 1,362 |
| Loss from discontinued operations, net of tax | -100 | -107 | -107 | -82 |
| Net income | 911 | -640 | 1,647 | 1,280 |
| Basic | 4,425,000 | 4,423,000 | 4,420,000 | 4,393,000 |
| Diluted | 27,695,000 | 4,423,000 | 27,704,000 | 4,423,000 |
| Net income (loss) per basic share of common stock | 0.21 | -0.14 | 0.37 | 0.29 |
| Net income (loss) per diluted share of common stock | 0.03 | -0.14 | 0.06 | 0.29 |
INTERPACE BIOSCIENCES, INC. (IDXG)
INTERPACE BIOSCIENCES, INC. (IDXG)